Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| DMK Pharmaceuticals Corporation | DMK | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.232 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.232 | 0.232 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.177 - 1.50 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.232 | USD |
DMK Pharmaceuticals Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 2.34M | - | - | - | -821.29 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
DMK Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/21/2024 | 13:23 | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security.. |
| 2/07/2024 | 16:19 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/06/2024 | 09:04 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/05/2024 | 08:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/31/2024 | 16:17 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/23/2024 | 16:23 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 1/23/2024 | 16:22 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/03/2024 | 16:03 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
| 1/03/2024 | 16:02 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/03/2024 | 16:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/21/2023 | 11:31 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/21/2023 | 07:15 | GlobeNewswire Inc. | DMK Pharmaceuticals Regains Full Rights to Commercialize.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DMK Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.5218 | 1.04 | 0.177 | 0.5379923 | 1,293,719 | -0.2898 | -55.54% |
| 1 Year | 0.7261 | 1.50 | 0.177 | 0.6419828 | 1,370,892 | -0.4941 | -68.05% |
| 3 Years | 0.7261 | 1.50 | 0.177 | 0.6419828 | 1,370,892 | -0.4941 | -68.05% |
| 5 Years | 0.7261 | 1.50 | 0.177 | 0.6419828 | 1,370,892 | -0.4941 | -68.05% |
DMK Pharmaceuticals Description
| Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19. |
